期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 13, 期 12, 页码 1475-1485出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2015.0176
关键词
-
类别
资金
- Eisai
- Bristol-Myers Squibb
- Genentech BioOncology
- Merck
- Novartis Oncology
- Novocure
- Boehringer Ingelheim Pharmaceuticals, Inc.
These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer. In the most recent version of these guidelines, the NCCN Breast Cancer Panel included a new section on the principles of preoperative systemic therapy. In addition, based on new evidence, the panel updated systemic therapy recommendations for women with hormone receptor-positive breast cancer in the adjuvant and metastatic disease settings and for patients with HER2-positive metastatic breast cancer. This report summarizes these recent updates and discusses the rationale behind them.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据